scholarly journals The association between vitamin D and acute rejection in human kidney transplantation: A systematic review and meta-analysis study

2021 ◽  
pp. 101410
Author(s):  
Mohammad Mirzakhani ◽  
Sheyda Mohammadkhani ◽  
Shirin Hekmatirad ◽  
Soudabeh Aghapour ◽  
Negar Gorjizadeh ◽  
...  
2021 ◽  
Author(s):  
Mohammad Mirzakhani ◽  
Sheyda Mohammadkhani ◽  
Shirin Hekmatirad ◽  
Soudabeh Aghapour ◽  
Negar Gorjizadeh ◽  
...  

Abstract Background: Vitamin D (VitD) deficiency is associated with several diseases such as multiple sclerosis, rheumatoid arthritis, respiratory infection, and so forth. In the field of transplantation (kidney transplantation), some studies reported that patients with VitD deficiency are of increased chance of acute rejection, but other studies did not show such a chance. On the other hand, since VitD is a modulatory factor and can reduce the inflammatory response, understanding the exact role of it in transplantation may contribute to tolerance condition in these patients.Methods: The electronic databases, including PubMed, Scopus, Embase, ProQuest, Web of Science, and Google Scholar, were searched for eligible studies. In general, 14 studies with a total of 4,770 patients were included in this meta-analysis. Regarding the methodological heterogeneity, we selected a random-effects combination model. Moreover, OR was chosen as an effect size for this study.Results: After the combination of 14 studies, we showed that patients in the VitD-deficient group had an 82% increased chance of acute rejection compared with patients in the VitD-sufficient group, and this effect was significant (OR 1.82; 95% confidence interval [CI] [1.29, 2.56]; I2 = 52.3%). This result was significant, and, regarding the narrow CI, it can be a conclusive result. Study quality and gender variables were the main sources of inconsistent results in the primary studies. Moreover, using meta-regression, we showed that VitD deficiency (independent from the estimated glomerular filtration rate (eGFR) of patients) increased the chance of acute rejection.Conclusion: The normal VitD status of patients a few days before and after transplantation can reduce the risk of acute rejection, as it has definite modulatory effects on immune cells.


2021 ◽  
Author(s):  
Mohammad Mirzakhani ◽  
Sheyda Mohammadkhani ◽  
Shirin Hekmatirad ◽  
Soudabeh Aghapour ◽  
Negar Gorjizadeh ◽  
...  

Abstract Background: Vitamin D (VitD) deficiency is associated with several diseases such as multiple sclerosis, rheumatoid arthritis, respiratory infection, and so forth. In the field of transplantation (kidney transplantation), some studies reported that patients with VitD deficiency are of increased chance of acute rejection, but other studies did not show such a chance. On the other hand, since VitD is a modulatory factor and can reduce the inflammatory response, understanding the exact role of it in transplantation may contribute to tolerance condition in these patients.Methods: The electronic databases, including PubMed, Scopus, Embase, ProQuest, Web of Science, and Google Scholar, were searched for eligible studies. In general, 14 studies with a total of 4,770 patients were included in this meta-analysis. Regarding the methodological heterogeneity, we selected a random-effects combination model. Moreover, OR was chosen as an effect size for this study.Results: After the combination of 14 studies, we showed that patients in the VitD-deficient group had an 82% increased chance of acute rejection compared with patients in the VitD-sufficient group, and this effect was significant (OR 1.82; 95% confidence interval [CI] [1.29, 2.56]; I2 = 52.3%). This result was significant, and, regarding the narrow CI, it can be a conclusive result. Study quality and gender variables were the main sources of inconsistent results in the primary studies. Moreover, using meta-regression, we showed that VitD deficiency (independent from the estimated glomerular filtration rate (eGFR) of patients) increased the chance of acute rejection.Conclusion: The normal VitD status of patients a few days before and after transplantation can reduce the risk of acute rejection, as it has definite modulatory effects on immune cells.


2020 ◽  
Vol 11 ◽  
Author(s):  
Mohammad Mirzakhani ◽  
Mehdi Shahbazi ◽  
Roghayeh Akbari ◽  
Ivana Dedinská ◽  
Eghlim Nemati ◽  
...  

2020 ◽  
Author(s):  
Mohammad Mirzakhani ◽  
Sheyda Mohammadkhani ◽  
Shirin Hekmatirad ◽  
Soudabeh Aghapour ◽  
Negar Gorjizadeh ◽  
...  

Abstract Background: Vitamin D (VitD) deficiency is associated with several diseases such as multiple sclerosis, rheumatoid arthritis, respiratory infection, and so forth. In the field of transplantation (kidney transplantation), some studies reported that patients with VitD deficiency are of increased risk of acute rejection, but other studies did not show such a risk. On the other hand, since VitD is a modulatory factor and can reduce the inflammatory response, understanding the exact role of it in transplantation may contribute to tolerance condition in these patients.Methods: The electronic databases, including PubMed, Scopus, Embase, ProQuest, Web of Science, and Google Scholar, were searched for eligible studies. In general, 14 studies with a total of 4,770 patients were included in this meta-analysis. Regarding the methodological heterogeneity, we selected a random-effects combination model. Moreover, OR was chosen as an effect size for this study.Results: After the combination of 14 studies, we showed that patients in the VitD-deficient group had an 82% increased risk of acute rejection compared with patients in the VitD-sufficient group, and this effect was significant (OR 1.82; 95% confidence interval [CI] [1.29, 2.56]; I2 = 52.3%). This result was significant, and, regarding the narrow CI, it can be a conclusive result. Study quality and gender variables were the main sources of inconsistent results in the primary studies. Moreover, using meta-regression, we showed that VitD deficiency (independent from the estimated glomerular filtration rate (eGFR) of patients) increased the risk of acute rejection.Conclusion: The normal VitD status of patients a few days before and after transplantation can reduce the risk of acute rejection, as it has definite modulatory effects on immune cells.


2021 ◽  
Author(s):  
Mohammad Mirzakhani ◽  
Sheyda Mohammadkhani ◽  
Shirin Hekmatirad ◽  
Soudabeh Aghapour ◽  
Negar Gorjizadeh ◽  
...  

Abstract Background: Vitamin D (VitD) deficiency is associated with several diseases such as multiple sclerosis, rheumatoid arthritis, respiratory infection, and so forth. In the field of transplantation (kidney transplantation), some studies reported that patients with VitD deficiency are of increased chance of acute rejection, but other studies did not show such a chance. On the other hand, since VitD is a modulatory factor and can reduce the inflammatory response, understanding the exact role of it in transplantation may contribute to tolerance condition in these patients.Methods: The electronic databases, including PubMed, Scopus, Embase, ProQuest, Web of Science, and Google Scholar, were searched for eligible studies. In general, 14 studies with a total of 4,770 patients were included in this meta-analysis. Regarding the methodological heterogeneity, we selected a random-effects combination model. Moreover, OR was chosen as an effect size for this study.Results: After the combination of 14 studies, we showed that patients in the VitD-deficient group had an 82% increased chance of acute rejection compared with patients in the VitD-sufficient group, and this effect was significant (OR 1.82; 95% confidence interval [CI] [1.29, 2.56]; I2 = 52.3%). This result was significant, and, regarding the narrow CI, it can be a conclusive result. Study quality and gender variables were the main sources of inconsistent results in the primary studies. Moreover, using meta-regression, we showed that VitD deficiency (independent from the estimated glomerular filtration rate (eGFR) of patients) increased the chance of acute rejection.Conclusion: The normal VitD status of patients a few days before and after transplantation can reduce the risk of acute rejection, as it has definite modulatory effects on immune cells.


2021 ◽  
Author(s):  
Xiaohong Lin ◽  
Miaohan Deng ◽  
Xitao Hong ◽  
Weiqiang Ju ◽  
Maogen Chen

Abstract BackgroundAnti-IL-2 antibody (basiliximab or daclizumab) and anti-thymocyte globulin (ATG)/antilymphocyte globulin (ALG) are widely used as induction agents in pediatric kidney transplantation. However, which of them benefits patients more remains unknown.MethodsOnline databases were searched to identify controlled clinical studies that compared anti-IL-2 with ATG/ALG for induction therapy in pediatric kidney transplantation. Odds ratios (OR) and 95% confidence interval (CI) were chosen to compare the gathered data. Review Manager 5.4 was applied to identify differences in outcomes between the two agents.ResultsFive retrospective cohort studies were included, enrolling a total of 2510 pediatric patients, 1152 (45.7%) of whom had received ATG/ALG therapy and 1370 (54.3%) of whom received anti-IL-2. According to the pooled results, no differences were seen between anti-IL-2 and ATG/ALG regarding the delayed graft function (DGF) rate (odds ratio (OR) 1.1; 95% confidence interval (CI) 0.36–3.39; P = 0.85), 6-month acute rejection rate (OR 0.80; 95% CI 0.62–1.03; P = 0.09), 1-year acute rejection rate (OR 0.98; 95% CI 0.78–1.24; P = 0.88), 1-year graft survival rate (OR 1.37; 95% CI 0.91–2.06; P = 0.13), 1-year patient survival rate (OR 0.86; 95% CI 0.40–1.86; P = 0.70) and 1-year post-transplantation lymphoproliferative disorder (PTLD) rate (OR 0.30; 95% CI 0.03–3.16; P = 0.32).ConclusionsAnti-IL-2 have the same efficacy and safety as ATG/ALG in transplant induction therapy. However, as most of included studies were small-scale retrospective studies, further studies are needed to identify an optimal choice with certain.The analysis had been registered in PROSPERO and the registration ID is CRD42021237561. Comparison of induction therapy with anti-thymocyte/antilymphocyte globulin or anti-IL-2 receptor antibody in pediatric kidney transplantation: a systematic review and meta-analysis


2017 ◽  
Vol 12 (5) ◽  
pp. 379-389 ◽  
Author(s):  
Gholamreza Badfar ◽  
Masoumeh Shohani ◽  
Akram Mansouri ◽  
Ali Soleymani ◽  
Milad Azami

2019 ◽  
Vol 16 (1) ◽  
Author(s):  
Xin Zheng ◽  
Lian Gong ◽  
Wenrui Xue ◽  
Song Zeng ◽  
Yue Xu ◽  
...  

Abstract Background Kidney transplantation is now a viable alternative to dialysis in HIV-positive patients who achieve good immunovirological control with the currently available antiretroviral therapy regimens. This systematic review and meta-analysis investigate the published evidence of outcome and risk of kidney transplantation in HIV-positive patients following the PRISMA guidelines. Methods Searches of PubMed, the Cochrane Library and EMBASE identified 27 cohort studies and 1670 case series evaluating the survival of HIV-positive kidney transplant patients published between July 2003 and May 2018. The regimens for induction, maintenance therapy and highly active antiretroviral therapy, acute rejection, patient and graft survival, CD4 count and infectious complications were recorded. We evaluated the patient survival and graft survival at 1 and 3 years respectively, acute rejection rate and also other infectious complications by using a random-effects analysis. Results At 1 year, patient survival was 0.97 (95% CI 0.95; 0.98), graft survival was 0.91 (95% CI 0.88; 0.94), acute rejection was 0.33 (95% CI 0.28; 0.38), and infectious complications was 0.41 (95% CI 0.34; 0.50), and at 3 years, patient survival was 0.94 (95% CI 0.90; 0.97) and graft survival was 0.81 (95% CI 0.74; 0.87). Conclusions With careful selection and evaluation, kidney transplantation can be performed with good outcomes in HIV-positive patients.


Sign in / Sign up

Export Citation Format

Share Document